Transient Ischemic Attack With Risperidone and Clonidine

McNicholas, Fiona; Motala, Farhana

doi:10.1097/chi.0b013e318157d9ac

Cited by 2 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A case study51 of an eleven-year-old with a tic disorder reported a transient ischemic attack while taking risperidone and clonidine. It is not clear whether the medications, or which of the two medications, caused the transient ischemic attack.…”

Section: Safetymentioning

confidence: 99%

Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders

Ming¹,

Mulvey²,

Mohanty³

et al. 2011

AHMT

View full text Add to dashboard Cite

Clonidine has been used off-label in children and adolescents with attention deficit and hyperactivity disorders (ADHD) with or without comorbidities. Clonidine extended-release was recently approved by the US Food and Drug Administration for ADHD in children. This review evaluates the efficacy and safety of clonidine extended-release and clonidine in children and adolescents with ADHD. A search of the Medline database and clinical trials register from 1996–2011 yielded ten clinical trials for critical evaluation of efficacy and safety. Eight of the ten trials reviewed were double-blinded and placebo-controlled. Nine of the ten trials utilized multiple outcome measures. Both clonidine extended-release and clonidine, as monotherapy or adjunctive therapy, were reported to be efficacious in treating ADHD symptoms in children and adolescents with or without comorbid disorders in nine of the ten clinical trials. One study showed clonidine to be ineffective in improving performance of a single task, at a specific point in time, in a small number of subjects. All of the studies that evaluated safety reported clonidine and clonidine extended-release to be well tolerated. The side effects of clonidine included somnolence, fatigue, headache, bradycardia, hypotension, and clinically insignificant electrocardiographic changes. However, there are historical anecdotal reports of serious cardiac side effects, including death in cases with other risk factors. None of the studies compared clonidine extended-release with clonidine in subjects with ADHD. Therefore, it is not clear whether clonidine extended-release is advantageous over clonidine, with regard to either efficacy or safety. It is equally unclear whether clonidine or clonidine extended-release is more efficacious in treating ADHD in subjects with comorbid disorders than in those without comorbidities. All the studies reviewed had limitations in their designs and methods. Clonidine and clonidine extended-release could be efficacious and safe for the treatment of ADHD both as monotherapy and as adjunctive therapy with stimulant medications in selected patients. There is a need for clinical trials to determine the long-term efficacy and safety of treatment with clonidine and clonidine extended-release in patients with ADHD.

show abstract

Section: Safetymentioning

confidence: 99%

Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders

Ming¹,

Mulvey²,

Mohanty³

et al. 2011

AHMT

View full text Add to dashboard Cite

show abstract

“…1 In 2001, as many as 14.9 per 1000 Medicaid-enrolled children were using atypical antipsychotics, despite the fact that these medications were not FDA approved for pediatric patients. 2 Although studies have found evidence of significant side effects in children, including weight gain, hyperlipidemia, hyperprolactinemia, extrapyramidal complications, potential cardiac arrythmias, and most recently, transient ischemic attacks, [3][4][5][6][7][8][9][10][11][12] evidence suggests that atypical antipsychotics may be effective in the treatment of behavior disorders, schizophrenia, and bipolar disorders. [13][14][15][16][17][18][19][20][21][22][23] Given this evidence, risperidone received FDA approval for the treatment of irritability associated with autism in October 2006 and for schizophrenia or bipolar disorder in August 2007.…”

Section: Introductionmentioning

confidence: 99%

Multiple Psychiatric Diagnoses Common in Privately Insured Children on Atypical Antipsychotics

Halloran

Swindle

Takemoto

2010

Clin Pediatr (Phila)

View full text Add to dashboard Cite

Objective To evaluate the prevalence of atypical antipsychotic use in privately insured children and the diagnoses associated with treatment. Study design Claims were used to conduct a retrospective cohort study of children aged 2 through 18 years in the Midwest, covered by private insurance between 2002 and 2005 (n = 172 766). The 1-year prevalence of children receiving atypical antipsychotics was determined along with associated diagnoses. Results The 1-year prevalence of atypical antipsychotics ranged from 7.9 per 1000 in 2002 to 9.0 in 2005. The leading diagnoses were disruptive behavior disorders (67%), mood disorders (65%), and anxiety disorders (43%). The authors found that 75% of children on atypical antipsychotics had more than one psychiatric diagnosis. Conclusions Atypical antipsychotic use is primarily seen in children who have multiple psychiatric diagnoses. Studies are needed to assess the long-term safety and effectiveness in such patients with multiple diagnoses.

show abstract

Transient Ischemic Attack With Risperidone and Clonidine

Cited by 2 publications

References 2 publications

Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders

Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders

Multiple Psychiatric Diagnoses Common in Privately Insured Children on Atypical Antipsychotics

Contact Info

Product

Resources

About